|Bid||20.25 x 1800|
|Ask||20.50 x 800|
|Day's range||20.45 - 20.50|
|52-week range||13.71 - 67.84|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.
Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. Thursday morning, Valneva announced that the committee for medicinal products for human use (CHMP) advising the European Medicines Agency (EMA) has recommended the jab be granted marketing authorization as a primary shot for adults 18 to 50 years old. The next step is for the European Commission (EC) to review the CHMP's recommendation and make a decision.
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.